Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurotrope, Inc.NTRP · Entity 144906 | See Remarks | December 01, 2020 | December 04, 2020 |
| Petros Pharmaceuticals, Inc.PTPI · Entity 8730 | Chief Accounting Officer | June 18, 2026 | June 25, 2026 |
| PharmaCyte Biotech, Inc.PMCB · Entity 8256 | Director | March 31, 2026 | July 17, 2026 |
| TAO Synergies Inc.TAOX · Entity 7482 | Chief Financial Officer | May 18, 2026 | May 19, 2026 |
| TaoWeave, Inc.OBLG · Entity 8246 | Director | May 29, 2023 | June 01, 2023 |
| XWELL, Inc.XWEL · Entity 1233 | Director | August 25, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurotrope, Inc.
Report date December 01, 2020 · Filed December 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 1
1 source rowRow 1 · 2020-12-01 · Disposition to issuer · Disposed 3,953 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.00 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-01 · Disposition to issuer · Disposed 20,313 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.60 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-01 · Disposition to issuer · Disposed 3,125 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-01 · Disposition to issuer · Disposed 7,768 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.62 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-01 · Disposition to issuer · Disposed 18,945 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-12-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-12-01 · Disposition to issuer · Disposed 135,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $25.00 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-01 · Disposition to issuer · Disposed 1,303 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.
F2: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held.
Petros Pharmaceuticals, Inc.
Report date June 18, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 636,004 |
Reported balance
Holding disclosure · report date 2026-06-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 636,004 F1: Includes (i) 6,004 restricted shares of common stock, par value $0.0001, of the Issuer, of which 3,004 shares are vested and the remainder of which will vest on February 2, 2027, (ii) 315,000 vested restricted stock units ("RSUs"), and (iii) 315,000 unvested RSUs, 2,500 of which will vest on July 2, 2026 and the remainder of which will vest on December 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes (i) 6,004 restricted shares of common stock, par value $0.0001, of the Issuer, of which 3,004 shares are vested and the remainder of which will vest on February 2, 2027, (ii) 315,000 vested restricted stock units ("RSUs"), and (iii) 315,000 unvested RSUs, 2,500 of which will vest on July 2, 2026 and the remainder of which will vest on December 5, 2026.
PharmaCyte Biotech, Inc.
Report date March 31, 2026 · Filed July 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-31 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-03-31 · Other · Acquired 0 · Balance 0 F1: The reported grant was made in error and has been cancelled. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported grant was made in error and has been cancelled.
TAO Synergies Inc.
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2036-05-18 | Direct | 30,000 |
Reported balance
After 2026-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 30,000 · Balance 30,000 F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026.
TaoWeave, Inc.
Report date May 29, 2023 · Filed June 01, 2023
This filing explicitly reported no securities owned.
XWELL, Inc.
Report date August 25, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 265,231 |
Reported balance
After 2026-08-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-25 · Grant · Acquired 50,000 · Balance 265,231 F1: Represents restricted shares of the Issuer's common stock, par value $0.01 which vested fully on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted shares of the Issuer's common stock, par value $0.01 which vested fully on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2026 Filed Sep 3, 2026 01:48 UTC | XWELL, Inc. XWEL · Entity 1233 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-104862 · tm2624717-5_4seq1.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,231 F1 · security: Represents restricted shares of the Issuer's common stock, par value $0.01 which vested fully on the date of grant. Read SEC document |
| May 18, 2026 Filed May 19, 2026 22:43 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001104659-26-063990 · tm2615135-2_4seq1.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock, par value $0.0001 per share · 30,000 shares Expires 2036-05-18 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:17 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 119,170 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001683168-26-002633 · ownership.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,170 Underlying: Common Stock · 119,170 shares Expires 2036-03-30 F1 · derivative.exercise_date: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Weinstein. Read SEC document |
| March 31, 2026 Filed Jul 17, 2026 21:00 UTC Amendment | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | OtherStock Option (Right to Buy) · Derivative | 0 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-26-005619 · ownership.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · security: The reported grant was made in error and has been cancelled. F1 · derivative.exercise_price: The reported grant was made in error and has been cancelled. F1 · date: The reported grant was made in error and has been cancelled. F1 · kind: The reported grant was made in error and has been cancelled. F1 · shares: The reported grant was made in error and has been cancelled. F1 · price: The reported grant was made in error and has been cancelled. F1 · derivative.exercise_date: The reported grant was made in error and has been cancelled. F1 · derivative.expiration_date: The reported grant was made in error and has been cancelled. F1 · derivative.underlying: The reported grant was made in error and has been cancelled. F1 · derivative.underlying_shares: The reported grant was made in error and has been cancelled. F1 · balance_after: The reported grant was made in error and has been cancelled. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 00:45 UTC | XWELL, Inc. XWEL · Entity 1233 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-022417 · tm267701-5_4seq1.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,231 F1 · security: Represents 100,000 restricted stock units ("RSUs"), which such RSUs shall vest on the thirtieth (30th) day following the date of grant, provided that the reporting person remains employed by or is providing services to the Issuer. The RSUs were granted subject to the closing of the transaction contemplated by that certain securities purchase agreement, dated as of February 24, 2026, by and between the Company and the purchaser signatory thereto, which occurred on February 27, 2026. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:08 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | Tax withholdingCommon Stock | 33,750 | $1.02 | $34,425.00 |
DisclosureSEC source: 0001683168-25-009116 · ownership.xml · nonDerivative · entry 2 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,250 F1 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:08 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-009116 · ownership.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Read SEC document |
| October 17, 2025 Filed Oct 17, 2025 21:14 UTC | TAO Synergies Inc. TAOX · Entity 7482 | Tax withholdingCommon Stock, par value $0.0001 per share | 4,000 | $7.23 | $28,920.00 |
DisclosureSEC source: 0001104659-25-100464 · tm2529010-6_4seq1.xml · nonDerivative · entry 2 WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,574 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document |
| October 17, 2025 Filed Oct 17, 2025 21:14 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-100464 · tm2529010-6_4seq1.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,574 F1 · balance_after: Includes (i) 10,000 restricted stock units granted on October 17, 2025, under TAO Synergies Inc.'s (the "Issuer") 2020 Equity Incentive Plan which vested immediately and (ii) 10,574 shares of common stock. Read SEC document |
| August 06, 2025 Filed Oct 17, 2025 21:14 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantEmployee Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001104659-25-100464 · tm2529010-6_4seq1.xml · derivative · entry 3 WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2035-07-14 F3 · date: The option grant was approved by a committee of the Issuer's board of directors on July 14, 2025 subject to shareholder approval of an amendment to the Company's 2020 Equity Incentive Plan (the "Plan") to increase the number of shares authorized for issuance of awards under the Plan. The Company received shareholder approval of the amendment to the Plan on August 6, 2025. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:06 UTC | TAO Synergies Inc. TAOX · Entity 7482 | Tax withholdingCommon Stock, par value $0.0001 per share | 6,164 | $7.85 | $48,387.40 |
DisclosureSEC source: 0001104659-25-065282 · tm2519649-5_4seq1.xml · nonDerivative · entry 2 WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,574 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:06 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 15,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-065282 · tm2519649-5_4seq1.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,738 F1 · balance_after: Includes (i) 15,410 restricted stock units granted on June 30, 2025, under the Issuer's 2020 Equity Incentive Plan which vested immediately upon issuance and (ii) 1,328 shares of common stock. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 12:01 UTC | XWELL, Inc. XWEL · Entity 1233 | GrantEmployee stock option (right to buy) · Derivative | 117,886 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001104659-25-055729 · tm2517003-2_4seq1.xml · derivative · entry 2 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,886 Underlying: Common Stock · 117,886 shares Expires 2035-06-02 F2 · security: Represents stock options to purchase up to 117,886 shares of Common Stock with such stock options vesting 100% on the first anniversary of the date of the grant, provided that the reporting person is providing services to the Company through such vesting date. F2 · derivative.exercise_date: Represents stock options to purchase up to 117,886 shares of Common Stock with such stock options vesting 100% on the first anniversary of the date of the grant, provided that the reporting person is providing services to the Company through such vesting date. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 12:01 UTC | XWELL, Inc. XWEL · Entity 1233 | GrantCommon Stock, par value $0.01 | 107,407 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-055729 · tm2517003-2_4seq1.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,231 F1 · price: The reporting person received fully vested restricted stock units, in consideration of the reporting person's Board fees decrease effective in the fourth quarter of 2024. Read SEC document |
| April 25, 2025 Filed Dec 12, 2025 22:08 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 63,233 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001683168-25-009116 · ownership.xml · derivative · entry 3 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,233 Underlying: Common Stock · 63,233 shares Expires 2035-04-24 F2 · derivative.exercise_date: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Weinstein. This transaction is late due to an inadvertent administrative error and not any error of Mr. Weinstein. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 23:37 UTC | XWELL, Inc. XWEL · Entity 1233 | GrantEmployee stock option (right to buy) · Derivative | 30,825 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001104659-24-120237 · tm2428798-4_4seq1.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,825 Underlying: Common Stock · 30,825 shares Expires 2034-11-15 F1 · security: Represents stock options to purchase up to 30,825 shares of Common Stock with such stock options vesting 100% on the first anniversary of the date of the grant, provided that the reporting person is providing services to the Company through such vesting date. F1 · derivative.exercise_date: Represents stock options to purchase up to 30,825 shares of Common Stock with such stock options vesting 100% on the first anniversary of the date of the grant, provided that the reporting person is providing services to the Company through such vesting date. Read SEC document |
| April 30, 2024 Filed Jul 17, 2024 20:59 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 38,009 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001683168-24-004918 · ownership.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,009 Underlying: Common Stock · 38,009 shares Expires 2034-04-30 F1 · derivative.exercise_date: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Weinstein. This transaction is late due to an inadvertent administrative error and not any error of Mr. Weinstein. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:02 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 61,248 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001683168-23-008434 · ownership.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,248 Underlying: Common Stock · 61,248 shares Expires 2033-11-20 Read SEC document |
| May 30, 2023 Filed May 31, 2023 12:32 UTC | XWELL, Inc. XWEL · Entity 1233 | PurchaseCommon Stock | 25,000 | $0.25 | $6,175.00 |
DisclosureSEC source: 0001062993-23-012491 · form4.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,485 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.2466 to $0.2480, inclusive. The reporting person undertakes to provide to XWELL, Inc., any security holder of XWELL, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 26, 2023 Filed May 30, 2023 12:34 UTC | XWELL, Inc. XWEL · Entity 1233 | PurchaseCommon Stock | 25,000 | $0.25 | $6,250.00 |
DisclosureSEC source: 0001062993-23-012403 · form4.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,485 Read SEC document |
| January 05, 2023 Filed Jan 10, 2023 02:37 UTC Amendment | XWELL, Inc. XWEL · Entity 1233 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001235110-23-000004 · edgar.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-01-05 F1 · security: This grant is pursuant to the directors compensation plan. F2 · derivative.exercise_date: The option vests in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each calendar quarter, such that the options will be fully vested as of December 31, 2023. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 20:00 UTC | XWELL, Inc. XWEL · Entity 1233 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0000950138-23-000008 · edgar.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-01-05 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F2 · derivative.exercise_date: The option vests in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2023. Read SEC document |
| December 16, 2022 Filed Dec 21, 2022 01:02 UTC | TAO Synergies Inc. SNPX · Entity 7482 | SaleCommon Stock, par value $0.0001 per share | 27,000 | $1.17 | $31,641.30 |
DisclosureSEC source: 0001104659-22-128771 · tm2233089-6_4seq1.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,198 F1 · shares: Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:02 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 96,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-22-119880 · tm2230820-5_4seq1.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock, par value $0.0001 per share · 96,000 shares Expires 2032-11-15 F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer. Read SEC document |
| November 15, 2022 Filed Dec 2, 2022 00:54 UTC Amendment | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-22-123808 · tm2231816-8_4aseq1.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock, par value $0.0001 per share · 75,000 shares Expires 2032-11-15 F1 · shares: This filing amends the Form 4, filed on November 17, 2022 by Mr. Weinstein to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended. F2 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 23:59 UTC | XWELL, Inc. XSPA · Entity 1233 | SaleCommon Stock | 45,000 | $1.06 | $47,700.00 |
DisclosureSEC source: 0000950138-22-000108 · edgar.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,485 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Reflects the correction of an error in Column 5 reported in the Reporting Person's Form 4 filed on January 31, 2022. Read SEC document |
| January 26, 2022 Filed Feb 1, 2022 01:19 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantStock Option (right to buy) · Derivative | 46,875 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0000950138-22-000034 · edgar.xml · derivative · entry 2 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Stock · 46,875 shares Expires 2032-01-26 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F3 · derivative.exercise_date: The options vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2022. Read SEC document |
| January 26, 2022 Filed Feb 1, 2022 01:19 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-22-000034 · edgar.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,485 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F2 · shares: Represents restricted stock units which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2022. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 22:08 UTC | XWELL, Inc. XSPA · Entity 1233 | SaleCommon Stock | 45,000 | $1.56 | $70,236.00 |
DisclosureSEC source: 0000950138-22-000023 · edgar.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,235 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.58, inclusive. The reporting person undertakes to provide to XpresSpa Group, Inc. any security holder of XpresSpa Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 20, 2021 Filed Oct 22, 2021 20:15 UTC | XWELL, Inc. XSPA · Entity 1233 | SaleCommon Stock | 63,000 | $1.43 | $90,209.70 |
DisclosureSEC source: 0000950138-21-000470 · edgar.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,235 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.41 to $1.44, inclusive. The reporting person undertakes to provide to XpresSpa Group, Inc. any security holder of XpresSpa Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 21:22 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-21-000394 · edgar.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,235 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F2 · shares: Represents restricted stock units which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of June 30, 2022. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 22:06 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-092716 · tm2122331-4_4seq1.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,198 F1 · balance_after: Includes 60,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:35 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantStock Option (right to buy) · Derivative | 43,077 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001235110-21-000002 · edgar.xml · derivative · entry 2 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,077 Underlying: Common Stock · 43,077 shares Expires 2031-01-04 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F3 · derivative.exercise_date: The option vests in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2021. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:35 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantCommon Stock | 28,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001235110-21-000002 · edgar.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,235 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F2 · shares: Represents restricted stock units which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2021. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 135,000 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0001104659-20-132150 · tm2037705d3_4.xml · derivative · entry 8 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 135,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $3.93 | Not disclosed |
DisclosureSEC source: 0001104659-20-132150 · tm2037705d3_4.xml · derivative · entry 7 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 18,945 | Not disclosed Strike: $19.62 | Not disclosed |
DisclosureSEC source: 0001104659-20-132150 · tm2037705d3_4.xml · derivative · entry 6 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,945 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 7,768 | Not disclosed Strike: $10.56 | Not disclosed |
DisclosureSEC source: 0001104659-20-132150 · tm2037705d3_4.xml · derivative · entry 5 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,768 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 3,125 | Not disclosed Strike: $25.60 | Not disclosed |
DisclosureSEC source: 0001104659-20-132150 · tm2037705d3_4.xml · derivative · entry 4 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerWarrant to Purchase Common Stock · Derivative | 1,303 | Not disclosed Strike: $25.00 | Not disclosed |
DisclosureSEC source: 0001104659-20-132150 · tm2037705d3_4.xml · derivative · entry 3 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,303 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 20,313 | Not disclosed Strike: $32.00 | Not disclosed |
DisclosureSEC source: 0001104659-20-132150 · tm2037705d3_4.xml · derivative · entry 2 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,313 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options or warrants, as applicable, were disposed of as follows: the reporting person received an option or warrant, as applicable, to purchase one (1) share of Petros Common Stock for every option or warrant, as applicable, to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerCommon Stock | 3,953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-132150 · tm2037705d3_4.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. Read SEC document |
| November 24, 2020 Filed Nov 27, 2020 22:07 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001104659-20-130074 · tm2037145d3_4seq1.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2030-11-24 F1 · derivative.exercise_date: The shares will immediately vest and become exercisable subject to and upon consummation of (1) the merger of PM Merger Sub 1, LLC with and into Metuchen Pharmaceuticals, LLC ("Metuchen"), with Metuchen surviving as a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. ("Petros") and (2) the merger of PN Merger Sub 2, Inc. with and into Neurotrope, Inc. ("Neurotrope"), with Neurotrope surviving as a wholly-owned subsidiary of Petros. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 23:58 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantStock Option (Right to Buy) · Derivative | 185,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001104659-20-049352 · tm2016454d3_4.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2030-04-20 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F1 · price: These securities were issued as part of the Issuer's equity grant to directors. F2 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, with one-fourth vesting on the date of grant and one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2020. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 23:02 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001144204-19-002685 · tv511525_4.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: The stock option award was made pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. The stock options shall vest according to the following schedule: 50% vest on the date of grant, with the remaining stock options vesting in equal quarterly installments over a two-year period following the date of grant. Read SEC document |
| April 11, 2017 Filed Apr 14, 2017 01:45 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 18,945 | $0.00 Strike: $19.62 | $0.00 |
DisclosureSEC source: 0001144204-17-020446 · v464201_4.xml · derivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,945 Underlying: Common Stock · 18,945 shares Expires 2027-04-11 F1 · security: Such option grant is subject to stockholder approval of the Issuer's 2017 Equity Incentive Plan under which the option was granted. F2 · derivative.exercise_date: The stock options vest in equal quarterly installments over a three-year period. Read SEC document |
| December 20, 2016 Filed Dec 20, 2016 17:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | OtherSeries C Warrant · Derivative | 41,667 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001144204-16-140449 · v455410_4.xml · derivative · entry 4 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,667 shares Expires 2020-11-13 Read SEC document |
| December 20, 2016 Filed Dec 20, 2016 17:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | OtherSeries A Warrant · Derivative | 41,667 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001144204-16-140449 · v455410_4.xml · derivative · entry 3 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,667 shares Expires 2020-11-13 Read SEC document |
| December 20, 2016 Filed Dec 20, 2016 17:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | OtherCommon Stock | 41,667 | $0.01 | $416.67 |
DisclosureSEC source: 0001144204-16-140449 · v455410_4.xml · nonDerivative · entry 2 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,438 Read SEC document |
| December 20, 2016 Filed Dec 20, 2016 17:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | OtherCommon Stock | 41,667 | $0.01 | $416.67 |
DisclosureSEC source: 0001144204-16-140449 · v455410_4.xml · nonDerivative · entry 1 WEINSTEIN ROBERT · CIK 0001213709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,771 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.